Cannabis-Based Products for Chronic Pain
Annals of Internal Medicine · 2026-02 · 179 (2) · 230-241
DOI: 10.7326/annals-25-03152 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Internal Medicine, 2026-02. Verfasst von Roger Chou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pacific Northwest Evidence-based Practice Center, Division of Medical Informatics, Clinical Epidemiology & Translational Data Science, Department of …. Hauptthemen laut MEDLINE: Chronic Pain, Cannabinoids, Medical Marijuana. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Themen: Schmerzmanagement
Abstract (Originalsprache)
BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: 25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services (PROSPERO: CRD42021229579).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pacific Northwest Evidence-based Practice Center, Division of Medical Informatics, Clinical Epidemiology & Translational Data Science, Department of Medicine, Oregon Health & Science University, Portland, Oregon (R.C.,…
- Pacific Northwest Evidence-based Practice Center, Division of Medical Informatics, Clinical Epidemiology & Translational Data Science, Department of Medicine, Oregon Health & Science University, Portland; and School of…
- Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland; and Department of Psychiatry, School of Medicine, Oregon Health & Science University, Portland, Oregon (B.J.M.).
ORCID-Profile: Roger Chou
Zitieren
APA
Chou, R., Fu, R., Ahmed, A. Y., & Morasco, B. J. (2026). Cannabis-Based Products for Chronic Pain. Annals of Internal Medicine, 179(2), 230-241. https://doi.org/10.7326/annals-25-03152
Vancouver
Chou R, Fu R, Ahmed AY, Morasco BJ. Cannabis-Based Products for Chronic Pain. Annals of Internal Medicine. 2026;179(2):230-241. doi:10.7326/annals-25-03152
BibTeX
@article{Chou2026,
author = {Chou, Roger and Fu, Rongwei and Ahmed, Azrah Y and Morasco, Benjamin J},
title = {Cannabis-Based Products for Chronic Pain},
journal = {Annals of Internal Medicine},
year = {2026},
volume = {179},
number = {2},
pages = {230--241},
doi = {10.7326/annals-25-03152}
}
EUVIMED